The neutralization titers induced by the IgEsig-prM-E mRNA LNPs were uniformly high (50% neutralization titer of ~1/10,000) in all three mouse models. genes and tested immunogenicity and protection in mice. Two doses of altered mRNA LNPs encoding prM-E genes that produced virus-like particles resulted in high neutralizing antibody titers (~ 1/100,000) that guarded against ZIKV contamination and conferred sterilizing immunity. To offset a theoretical concern of ZIKV vaccines inducing antibodies that AZD2014 (Vistusertib) cross-react with the related Dengue computer virus (DENV), we designed altered prM-E RNA encoding mutations destroying the conserved fusion-loop epitope in the E protein. This variant guarded against ZIKV and diminished production of antibodies enhancing DENV contamination in cells or mice. A altered mRNA vaccine can prevent ZIKV disease and be adapted to reduce the risk of sensitizing individuals to subsequent exposure to DENV, should this become a clinically-relevant concern. species mosquitoes and non-human primates, and episodically spilled into human populations in parts of Africa and Asia. Prior to 2010, ZIKV Contamination was described as a self-limiting febrile illness with headache, rash, conjunctivitis, and myalgia. More recently, and especially in the context of its AZD2014 (Vistusertib) spread in the Western Hemisphere, more severe clinical consequences have been observed (Lazear and Diamond, 2016). Contamination of fetuses during pregnancy has been associated with placental insufficiency and congenital malformations including cerebral calcifications, microcephaly, and miscarriage (Brasil et al., 2016; Rasmussen et al., 2016; van der Eijk et al., 2016). In adults, ZIKV contamination is linked to Guillain-Barr syndrome (GBS), an autoimmune disease characterized by paralysis and polyneuropathy (Cao-Lormeau et al., 2016; Oehler et al., 2014). Sexual transmission of ZIKV also has been described from men-to-women (Foy et al., 2011), men-to-men (Deckard et al., 2016), and women-to-men (Davidson et al., 2016). Persistent ZIKV has been detected in semen, sperm, and vaginal secretions up to 6 months following contamination (Mansuy et al., 2016; Murray et al., 2017). ZIKV is now a global disease of the Americas, Africa, and Asia. ZIKV is usually a member of the Flavivirus genus of the family of enveloped RNA viruses. ZIKV has an ~11 kb positive sense RNA genome. Translation of viral RNA in the cytoplasm generates a polyprotein that is cleaved into three structural proteins (capsid (C), pre-membrane/membrane (prM/M), and envelope (E)) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). ZIKV buds into the lumen of the endoplasmic reticulum as an immature virion composed of 60 icosahedrally arranged prM-E heterotrimers (Prasad et al., 2017). As GU2 the computer virus transits through the secretory pathway, the acidic environment of the Golgi network triggers exposure of a furin protease cleavage site within prM. Cleavage of prM and release of the pr peptide AZD2014 (Vistusertib) in the extracellular space produces mature, infectious virions that display 90 antiparallel E homodimers on their surface. The ZIKV E protein is composed of three ectodomains (DI, DII, and DIII) and is the primary target of neutralizing antibodies. Potently inhibitory monoclonal antibodies (mAbs) against ZIKV target epitopes in all three E protein domains as well as quaternary structures composed of multiple domains within or across E dimers (Barba-Spaeth et al., 2016; Sapparapu et al., 2016; Stettler et al., 2016; Swanstrom et al., 2016; Wang et al., 2016; Zhao et al., 2016). In addition to induction by infectious or inactivated computer virus particles, neutralizing antibodies against ZIKV can be produced after immunization with DNA plasmids encoding M-E protein (Larocca et al., 2016) or prM-E, which in some cases generates secreted virus-like subviral particles (SVPs) (Dowd et al., 2016b; Muthumani et al., 2016). The presence of two ZIKV lineages, African and Asian/American (Haddow et al., 2012) does not impact antibody neutralization substantively and thus, ZIKV is classified as a single serotype (Dowd et al., 2016a). ZIKV is related to several pathogens that cause disease globally including Dengue (DENV), yellow fever (YFV), West Nile (WNV), Japanese encephalitis (JEV), and tick-borne encephalitis (TBEV) viruses. Of these viruses, ZIKV is usually most closely related to the four serotypes of DENV as it shares 54 to 59% amino acid identity in the viral E protein (Dejnirattisai et al., 2016). Because of its potential to infect and cause harm to developing fetuses and neonates (Huang et al., 2016), presently there is an urgent call to develop countermeasures (Marston et al., 2016). Several groups have developed subunit (prM-E or M-E DNA plasmid or adenovirus-vectored) or inactivated computer virus vaccine platforms capable of eliciting neutralizing antibodies that protect against ZIKV viremia in mice and non-human primates (Abbink et al., 2016; Dowd et al., 2016b; Larocca et al., 2016; Muthumani et al., 2016). Some of these vaccine candidates have initiated or AZD2014 (Vistusertib) are scheduled to begin recruitment of subjects for evaluation in humans (“type”:”clinical-trial”,”attrs”:”text”:”NCT02840487″,”term_id”:”NCT02840487″NCT02840487, “type”:”clinical-trial”,”attrs”:”text”:”NCT02887482″,”term_id”:”NCT02887482″NCT02887482, “type”:”clinical-trial”,”attrs”:”text”:”NCT02809443″,”term_id”:”NCT02809443″NCT02809443, “type”:”clinical-trial”,”attrs”:”text”:”NCT02937233″,”term_id”:”NCT02937233″NCT02937233, “type”:”clinical-trial”,”attrs”:”text”:”NCT02952833″,”term_id”:”NCT02952833″NCT02952833, and “type”:”clinical-trial”,”attrs”:”text”:”NCT02963909″,”term_id”:”NCT02963909″NCT02963909). The sequence similarity between ZIKV and DENV poses issues for vaccine development.